Elizabeth Glaser/Pediatric AIDS Foundation/DFIDPriorities for the development of new HIV medications for children include a complete dolutegravir-based regimen than can be mixed with water, an improved protease inhibitor for second-line treatment and injectable cabotegravir for infant prophylaxis. Looking further forward, a World Health Organization group recommends the development of new technologies such as skin patches that would make adherence easier and investigation of broadly neutralising antibodies for infants.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.